Publication:
Comparison of direct oral anticoagulants and low-molecular-weight heparins in cancer patients with nonvalvular atrial fibrillation: insights from a single-center experience

Simple item page
dc.contributor.coauthorCeren, İ.
dc.contributor.coauthorŞener, Y. Z.
dc.contributor.coauthorGöçer, K.
dc.contributor.coauthorGülgün Fırat, H.
dc.contributor.coauthorYıldız, F.
dc.contributor.coauthorBozduman Habip, F.
dc.contributor.coauthorAçıkgöz, E.
dc.contributor.coauthorAteş, Ö.
dc.contributor.coauthorGerede Uludağ, D. M.
dc.contributor.coauthorEroğlu Büyüköner, E.
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.kuauthorTokdil, Nafia İnan Kardelen Ohtaroğlu
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.date.accessioned2026-07-19T19:48:32Z
dc.date.issued2026
dc.description.abstractAtrial fibrillation (AF) is frequently encountered in patients with cancer and poses challenges for anticoagulant management. The present study was conducted to compare clinical outcomes associated with direct oral anticoagulants (DOACs) and low-molecular-weight heparin (LMWH) in individuals with active malignancy and nonvalvular AF (NVAF). METHODS: Data from patients with active cancer who received LMWH or DOACs for NVAF were retrospectively screened. Efficacy, safety, and survival outcomes were analyzed. RESULTS: The study enrolled 222 patients, of whom 25.7% received LMWH and 74.3% received DOACs. Cancer stage, type, and treatment were comparable between groups. The DOAC group had higher CHA2DS2-VA (3.13 ± 1.21 vs. 2.42 ± 1.33; P
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuN/A
dc.description.versionPublished Version
dc.identifier.ScopusPercentile50
dc.identifier.ScopusQuartileQ2
dc.identifier.WoSPercentile42.0
dc.identifier.WoSQuartileQ3
dc.identifier.doi10.14744/anatoljcardiol.2026.5923
dc.identifier.eissn2149-2271
dc.identifier.embargoN/A
dc.identifier.issn2149-2263
dc.identifier.pubmed42370541
dc.identifier.urihttp://doi.org/10.14744/anatoljcardiol.2026.5923
dc.identifier.urihttps://hdl.handle.net/20.500.14288/33554
dc.identifier.wos001812934600001
dc.keywordsAtrial fibrillation
dc.keywordsCancer
dc.keywordsCardio-oncology
dc.keywordsDirect oral anticoagulants
dc.keywordsLow-molecular-weight heparin
dc.languageeng
dc.publisherKare
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofAnatolian Journal of Cardiology
dc.relation.openaccessN/A
dc.rightsN/A
dc.rights.uriN/A
dc.subjectHealth sciences
dc.subjectMedicine
dc.subjectCardiology and cardiovascular medicine
dc.titleComparison of direct oral anticoagulants and low-molecular-weight heparins in cancer patients with nonvalvular atrial fibrillation: insights from a single-center experience
dc.typeJournal Article
dspace.entity.typePublication
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication.latestForDiscovery055775c9-9efe-43ec-814f-f6d771fa6dee

Files

Collections

Publications without Fulltext